###begin article-title 0
###xml 98 120 <span type="species:ncbi:272636">adeno-associated virus</span>
Reduction of experimental diabetic vascular leakage by delivery of angiostatin with a recombinant adeno-associated virus vector
###end article-title 0
###begin p 1
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Purpose
###end title 2
###begin p 3
###xml 40 62 <span type="species:ncbi:272636">adeno-associated virus</span>
###xml 88 93 <span type="species:ncbi:10090">mouse</span>
###xml 196 199 <span type="species:ncbi:10116">rat</span>
To evaluate the efficacy of recombinant adeno-associated virus (rAAV) vector expressing mouse angiostatin (Kringle domains 1 to 4) in reducing retinal vascular leakage in an experimental diabetic rat model.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 78 97 <span type="species:ncbi:10116">Sprague-Dawley rats</span>
###xml 489 495 <span type="species:ncbi:9913">bovine</span>
rAAV-angiostatin was delivered by intravitreal injection to the right eyes of Sprague-Dawley rats. As a control, the contralateral eye received an intravitreal injection of rAAV-lacZ. Gene delivery was confirmed by reverse-transcriptase polymerase chain reaction (RT-PCR). Diabetes was induced by intravenous injection of streptozotocin (STZ). Vascular permeability changes were evaluated by extravascular albumin accumulation and leakage of intravenous-injected fluorescein isothiocynate-bovine serum albumin (FITC-BSA). Effects of rAAV-angiostatin on expression of vascular endothelial growth factor (VEGF), pigment epithelium-derived factor (PEDF), occludin, and phospho-p42/p44 MAP kinase in retina tissue were analyzed by western blotting.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
The rAAV-angiostatin injections led to sustained angiostatin gene expression in retina as confirmed by RT-PCR, and reduced extravascular albumin accumulation in STZ-induced diabetic retina. Further, rAAV-angiostatin significantly decreased intravascularly injected FITC-BSA leakage at 5 days (p=0.001), 10 days (p<0.001), and 15 days (p=0.001) after STZ-induced diabetes, as compared to the control eyes receiving rAAV-lacZ. Expression of VEGF and phosphorylation of p42/p44 MAP kinase in retina was reduced by rAAV-angiostatin at day 1 (p=0.043 for both VEGF and phospho-p42/p44 MAP kinase) after STZ-induced diabetes compared with rAAV-lacZ eyes. rAAV-angiostatin reduced retinal occludin loss at 10 days after STZ-induced diabetes (n=5, p=0.041). There was no significant difference in retinal PEDF expression between eyes injected with rAAV-angiostatin and rAAV-lacZ.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 368 376 <span type="species:ncbi:9606">patients</span>
Intravitreal delivery of rAAV-angiostatin reduces vascular leakage in an STZ-induced diabetic model. This effect is associated with a reduction in the retinal occludin loss induced by diabetes and downregulation of retinal VEGF and phosphor-p42/p44 MAP kinase expression. This gene transfer approach may reduce diabetic macular edema, providing protection in diabetic patients at risk for macular edema.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 82 83 82 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 159 160 159 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 161 162 161 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 338 339 338 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 340 341 340 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 473 474 473 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 463 471 <span type="species:ncbi:9606">patients</span>
Diabetes mellitus is the most prevalent endocrine disease in developed countries [1], and diabetic retinopathy is the leading cause of blindness in the world [2,3]. Blood-retinal barrier (BRB) breakdown, increased vascular permeability and vascular leakage are early complications of diabetes and a major cause of diabetic macular edema [4-6]. As there is no satisfactory or noninvasive therapy, diabetic macular edema is a major cause of vision loss in diabetic patients [7].
###end p 11
###begin p 12
###xml 356 357 356 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 507 508 507 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 229 251 <span type="species:ncbi:272636">adeno-associated virus</span>
An ideal treatment strategy would be to deliver a therapeutic gene with a vector that could confer long-term transgene expression and tissue protection with a single administration. We have previously reported that a recombinant adeno-associated virus vector expressing angiostatin (rAAV-angiostatin) suppressed laser-induced choroidal neovascularization [8]. Recently, an effect of angiostatin in reducing vascular permeability in the retina in diabetic and oxygen-induced retinopathy models was reported [9].
###end p 12
###begin p 13
###xml 77 79 77 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 316 318 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 445 446 445 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 447 449 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 450 452 450 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 652 654 652 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
Angiostatin (Kringles 1 through 4) is a proteolytic fragment of plasminogen [10]. It was identified as a potent angiogenic inhibitor, which blocks neovascularization and suppresses tumor growth and metastases [10,11]. Angiostatin specifically inhibits proliferation, induces apoptosis in vascular endothelial cells [12], and downregulates vascular endothelial growth factor (VEGF), the latter via inactivation of the p42/p44 MAP kinase pathway [9,13,14]. We also noted that some proteolytic fragments of plasminogen can induce upregulation of pigment epithelium-derived factor (PEDF) expression, a potent angiogenic inhibitor in experimental diabetes [15].
###end p 13
###begin p 14
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 391 393 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 415 417 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 495 497 495 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
BRB breakdown may be due to disassembly of unique proteins that constitute the functional vascular endothelial tight junction [16-18]. VEGF is a potent angiogenic factor [13], whose overproduction in the retina has been noted in the development of vascular hyperpermeability in diabetes [14]. Furthermore, VEGF affects the tight junction protein occludin, inducing occludin phosphorylation [19] and redistribution [20]; resultant occludin reduction is associated with BRB breakdown in diabetes [21].
###end p 14
###begin p 15
###xml 335 336 335 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 337 339 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 340 342 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
The present study was designed to examine the transgenic expression of rAAV-angiostatin in the eye and its effect on vascular permeability in the streptozotocin (STZ)-induced diabetic model. Since it has been demonstrated angiostatin can induce the downregulation of VEGF through the blockade of phosphorylation of p42/p44 MAP kinase [9,13,14], we also studied the relationship between rAAV-angiostatin, p42/p44 MAP kinase, occludin, VEGF, and PEDF in this model.
###end p 15
###begin title 16
Methods
###end title 16
###begin title 17
Animals
###end title 17
###begin p 18
###xml 25 29 <span type="species:ncbi:10116">rats</span>
Male Sprague-Dawley (SD) rats (Charles River Laboratories, WilmingtonMA) weighing approximately 200 g on arrival were used in this study. The animals were cared for in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. All experimental procedures used aseptic sterile techniques and were approved by the Animal Care and Use Committee of the Mackay Memorial Hospital.
###end p 18
###begin title 19
Generation of rAAV-angiostatin
###end title 19
###begin p 20
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 252 254 252 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
###xml 383 385 383 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 129 134 <span type="species:ncbi:10090">mouse</span>
cDNA coding for angiostatin was amplified by polymerase chain reaction (PCR) according to a published report [22]. rAAV encoding mouse angiostatin cDNA or lacZ were constructed by using a three-plasmid cotransfection system as described previously [22-24]. Titers of rAAV-angiostatin and rAAV-lacZ were determined by dot blot hybridization using angiostatin cDNA and lacZ as probes [25].
###end p 20
###begin title 21
Intravitreal injections of rAAV-angiostatin
###end title 21
###begin p 22
###xml 108 110 107 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sup>
###xml 153 155 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 188 191 <span type="species:ncbi:10116">rat</span>
After being anesthetized, each animal received an intravitreal injection of rAAV- angiostatin (5 mul, 1.5x1010 viral particles) as described previously [26]. The contralateral eye of each rat was injected with rAAV-lacZ to serve as a control.
###end p 22
###begin title 23
Experimental Diabetes
###end title 23
###begin p 24
###xml 331 333 331 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 356 360 <span type="species:ncbi:10116">rats</span>
###xml 446 450 <span type="species:ncbi:10116">rats</span>
Experimental diabetes was induced three weeks after intravitreal injection of rAAV. Diabetes was induced with a single 60 mg/kg intravenous injection of streptozotocin (Sigma-Aldrich, St. Louis, MO) in 10 mM citrate buffer, pH 4.5. Animals that served as nondiabetic controls received an equivalent amount of citrate buffer alone [21] Twenty-four h later, rats with blood glucose levels higher than 250 mg/dl were deemed diabetic. These diabetic rats received 6-8U NPH insulin (Lilly, Indianapolis, IN) once a week to prevent ketoacidosis. Just before experimentation, blood glucose levels were measured again to confirm diabetic status.
###end p 24
###begin title 25
Reverse transcription-polymerase chain reaction
###end title 25
###begin p 26
###xml 113 114 113 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 122 125 <span type="species:ncbi:10116">rat</span>
Expression of rAAV-angiostatin in retina was confirmed by RT-PCR according to a protocol described in reference [8]. Each rat eye that was previously injected with rAAV-angiostatin and rAAV-lacZ was enucleated, and chorioretinal tissues were harvested for RT-PCR at 1, 5, 10, and 15 days after induction of experimental diabetes. The cDNA was synthesized using oligo(dT) primer and 200 IU transcriptase (SuperScript II; Life Technologies, Carlsbad, CA) according to the manufacturer's instructions. PCR amplification was performed with two oligonucleotide primers, 5'-CAG CAA TGC GTG ATC ATG-3' and 5'-TGG AGA TTT TGC CCT CAT AC-3'. As a control, PCR amplification was performed for glyceradehyde-3-phosphate dehydrogenase (GAPDH) with two oligonucleotide primers, 5'-GGA AGG GCT CAT GAC CAC AG-3' and 5'-CCT TTA GTG GGC CCT CGG-3'. To rule out the possibility that gene amplification products were derived from amplification of contaminating angiostatin genomic DNA, we treated the total RNA with RNase free DNase I (Qiagen, Valencia, CA) before RT-PCR.
###end p 26
###begin title 27
Immunofluorescence assay
###end title 27
###begin p 28
###xml 216 218 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r27">27</xref>
###xml 299 305 <span type="species:ncbi:9986">rabbit</span>
Five-mum-thick retinal tissue sections from formalin-fixed, paraffin-embedded blocks were transferred to positively charged slides to be used for staining. Sections were dewaxed in xylene and progressively hydrated [27]. They were then washed three times with PBS and a 1:400 dilution of polyclonal rabbit antihuman albumin antibody (DAKO Diagnostics. Mississauga, ON, Canada) was applied. A fluorescein isothiocyanate (FITC)-conjugated antimouse IgG was used as a secondary antibody. The results were viewed with a fluorescence microscope (Zeiss Axioplan HBO100, Oberkochen, Germany).
###end p 28
###begin title 29
Measurement of leakage with intravascular injected FITC-BSA
###end title 29
###begin p 30
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r28">28</xref>
###xml 773 774 770 771 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 172 176 <span type="species:ncbi:10116">rats</span>
###xml 225 231 <span type="species:ncbi:9913">bovine</span>
###xml 584 587 <span type="species:ncbi:10116">rat</span>
Retinal vascular leakage was measured using the intravascular injected FITC-BSA as previously described [21,28] with some modifications. After induction of anesthesia, the rats received tail vein injections of 100 mg/kg FITC-bovine serum albumin (FITC-BSA, Sigma-Aldrich). The animals were sacrificed 20 min later, and their eyes were removed, embedded in OCT medium, and snap-frozen in liquid nitrogen. The plasma was collected and assayed for fluorescence with an SPEX fluorescence spectrophotometer (Molecular Devices, Sunnyvale, CA) based on standard curves of FITC-BSA in normal rat plasma. Frozen retinal sections (6 mum thick) collected every 60 mum were viewed with a Zeiss Axioplan HBO100 fluorescence microscope. Images from six retinal nonvascular areas (200 mum2) in each section were collected. Quantification of FITC-BSA fluorescence intensity was calculated by computer software Q-win (Leica, Wetzlar, Germany) and normalized to plasma fluorescence intensity for each animal.
###end p 30
###begin title 31
Western blot analysis of VEGF, PEDF, occludin, and p42/p44 MAP kinase
###end title 31
###begin p 32
###xml 372 373 372 373 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 375 376 375 376 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 601 603 600 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
###xml 604 606 603 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r30">30</xref>
###xml 615 617 614 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r31">31</xref>
###xml 640 642 639 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 716 718 715 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 0 4 <span type="species:ncbi:10116">Rats</span>
Rats were sacrificed, and their eyes were removed for western blotting analysis at 1, 5, 10, and 15 days after STZ treatment. The chorioretinal tissue was harvested, and the soluble fractions were prepared by homogenizing the retina in Eppendorf tubes containing RIPA lysis buffer (50 mM Tris, 150 mM NaCl, 10 mM EDTA, 0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate, 1 mM Na3VO4, 1 mM NaF, 1 mM EGTA, 1 mM PMSF, 1 mg/ml leupeptin, and 1 mg/ml pepstatin A). Proteins (50 mug) were extracted for electrophoresis on 10% SDS-polyacrylamide gels. The membranes were incubated with antibody specific to VEGF [29,30], PEDF [31], p42/p44 MAP kinase [21] (all from Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and occludin [20] (Zymed, San Francisco, CA). The results were semiquantified by densitometry (Fujifilm LAS3000, Tokyo, Japan) and normalized to actin levels.
###end p 32
###begin title 33
Cell culture and rAAV-angiostatin infection
###end title 33
###begin p 34
###xml 422 423 416 417 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 110 115 <span type="species:ncbi:9606">human</span>
To further evaluate whether angiostatin could induce the expression of PEDF in endothelial cells, we infected human umbilical vein endothelial cells (HUVEC-2C, Cascade Biologics, Portland, OR) with rAAV-angiostatin. The HUVEC-2C cells were cultured in medium 200 (Cascade Biologics) containing low serum growth supplement. All cells were supplemented with 1% penicillin-streptomycin and maintained at 37 degreesC and 5% CO2. Confluent cells obtained during the fifth passage were used for rAAV-angiostatin infection. The HUVEC-2C cells were infected by rAAV-angiostatin in Dulbeco's modified Eagle's medium for two days. Cell lysates were then prepared and analyzed for PEDF by western blotting as described in the previous paragraph.
###end p 34
###begin title 35
Statistical Analyses
###end title 35
###begin p 36
###xml 134 138 <span type="species:ncbi:10116">rats</span>
The results are expressed as the mean+/-SD. Retinal FITC-BSA fluorescence intensity was analyzed in serial retinal sections from four rats at 5, 10, and 15 days after induction of diabetes. Due to skewed distributions, data were subjected to logarithmic transformation for analysis. Differences of retinal FITC-BSA fluorescence intensity between eyes receiving rAAV-angiostatin and rAAV-lacZ injection at 5, 10, and 15 days after induction of diabetes were analyzed by a paired-sample Student's t test. The retinal expression of VEGF, PEDF, phosporylation of p42/p44 MAPK, and occludin were analyzed by the Wilcoxon signed-rank test. All p-values are two-tailed, and differences were considered to be statistically significant for p<0.05.
###end p 36
###begin title 37
Results
###end title 37
###begin title 38
Gene delivery by rAAV-angiostatin
###end title 38
###begin p 39
###xml 65 73 65 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 170 178 170 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 331 339 331 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 499 507 499 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
There was no angiostatin gene expression in normal control eyes (Figure 1, lane A) and eyes injected with rAAV-lacZ at 1, 5, 10, and 15 days after induction of diabetes (Figure 1, lanes B-E). In the eyes injected with rAAV-angiostatin, angiostatin gene expression was detected at 1, 5, 10, and 15 days after induction of diabetes (Figure 1, lanes F-I). As an internal control, expression of GAPDH was detected in normal control eye and eyes receiving both rAAV-angiostatin and rAAV-lacZ injections (Figure 1, lanes A-I).
###end p 39
###begin p 40
RT-PCR analysis of angiostatin cDNA in chorioretinal tissue. The eyes previously injected with rAAV-lacZ (lanes B to E) and rAAV-angiostatin (lanes F to I) were enucleated and chorioretinal tissues were harvested for RT-PCR at 1, 5, 10, and 15 days after induction of experimental diabetes. Lane A is the control eye. Lanes B and F are 1 day after diabetes induction. Lanes C and G are 5 days after diabetes induction. Lanes D and H are 10 days after diabetes induction. Lanes E and I are 15 days after diabetes induction. There was no angiostatin gene expression in the control eye (lane A) and eyes injected with rAAV-lacZ (lanes B to E). In the eyes injected with rAAV-angiostatin, angiostatin gene expression was detected (lanes F to I). As an internal control, expression of GAPDH was detected in normal control eye and eyes receiving both rAAV-angiostatin and rAAV-lacZ injections (lanes A to I). "M" indicates molecular weight markers.
###end p 40
###begin title 41
Induction of experimental diabetes
###end title 41
###begin p 42
###xml 293 300 293 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
Animals (n=12) with a blood glucose exceeding 250 mg/dl were selected for inclusion in the diabetic group. All diabetic animals had higher blood glucose levels and reduced body weight gain at 5, 10, and 15 days after induction of diabetes compared to age-matched, nondiabetic control animals (Table 1).
###end p 42
###begin title 43
Animal physiological variables.
###end title 43
###begin p 44
Animals were made diabetic by a single streptozocin (STZ) injection (65 mg/kg) in 1 mmol/l sodium citrate buffer, pH 4.5. All diabetic animals had higher blood glucose levels and reduced body weight gain compared to age matched, non-diabetic control animals.
###end p 44
###begin title 45
rAAV-angiostatin influence on vascular permeability
###end title 45
###begin p 46
###xml 166 175 166 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2A</xref>
###xml 298 307 298 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2B</xref>
###xml 429 438 429 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2C</xref>
One week after induction of diabetes, the immunofluorescence assay, using anti-albumin antibody, disclosed staining only inside blood vessels in normal control eyes (Figure 2A). Increased extravascular albumin in the retinal parenchyma was seen in the eyes of diabetic animals receiving rAAV-lacZ (Figure 2B). In the diabetic animals receiving rAAV- angiostatin, however, albumin staining was observed only inside blood vessels (Figure 2C).
###end p 46
###begin p 47
###xml 209 210 209 210 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 255 256 255 256 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 306 307 306 307 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 235 253 <span type="species:ncbi:10116">Sprague-Dawley rat</span>
Representative retinal sections following immunostaining for albumin. Increased immunostaining was present throughout the retina one week after STZ-induction of diabetes in eyes receiving rAAV-lacZ injection (B) compared to the normal Sprague-Dawley rat (A) where staining was restircted to blood vessels. C: Intravitreal injection of rAAV-angiostatin decreased immunostaining in the retina one week after induction of diabetes. Magnification X200. IPL denotes the inner plexiform layer, INL indicates the inner nuclear layer, and ONL marks the outer nuclear layer.
###end p 47
###begin p 48
###xml 171 179 171 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3</xref>
###xml 348 357 348 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3B</xref>
###xml 493 502 493 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3C</xref>
###xml 596 605 596 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3D</xref>
###xml 615 624 615 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3E</xref>
###xml 801 810 801 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3F</xref>
###xml 890 899 890 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3G</xref>
###xml 909 918 909 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3H</xref>
###xml 268 272 <span type="species:ncbi:10116">rats</span>
To confirm the effect of rAAV-angiostatin on vascular permeability, we examined animals injected with intravenous FITC-BSA 5, 10, and 15 days after induction of diabetes. Figure 3 shows representative micrographs of the eyes of normal control and STZ-induced diabetic rats. FITC-BSA fluorescence is limited to the vasculature in the normal retina (Figure 3B) and diffusely increased throughout the retinal parenchyma at 5 days after STZ-induced diabetes in eyes receiving rAAV-lacZ injection (Figure 3C). Increased fluorescence intensity throughout the retinal parenchyma is still present at 10 (Figure 3D) and 15 (Figure 3E) days after STZ-induced diabetes in eyes receiving rAAV-lacZ injection. Little fluorescence was present in the retinal parenchyma in eyes receiving rAAV-angiostatin injection (Figure 3F) at 5 days after induction of diabetes. Retinal parenchyma fluorescence at 10 (Figure 3G) and 15 (Figure 3H) days after induction of diabetes in eyes with rAAV-angiostatin injection was decreased as compared with eyes that received the rAAV-lacZ injection.
###end p 48
###begin p 49
###xml 86 87 86 87 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 139 140 139 140 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 222 223 222 223 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 448 449 448 449 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 459 460 459 460 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 533 534 533 534 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 717 718 717 718 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</bold>
###xml 728 729 728 729 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</bold>
###xml 74 77 <span type="species:ncbi:10116">rat</span>
FITC-BSA fluorescence in normal and streptozotocin (STZ)-induced diabetic rat retina. A: Hematoxylin and eosin staining of control retina. B: FITC-BSA fluorescence is limited to the vasculature in the normal retina and in C is diffusely increased throughout the retinal parenchyma at 5 days after STZ-induced diabetes in eyes receiving rAAV-lacZ injection. Increased fluorescence intensity throughout the retinal parenchyma is still present at 10 (D) and 15 (E) days after STZ-induced diabetes in eyes receiving rAAV-lacZ injection. F: Little fluorescence was present in the retinal parenchyma in eyes receiving rAAV-angiostatin injection at 5 days after induction of diabetes. Retinal parenchyma fluorescence at 10 (G) and 15 (H) days after induction of diabetes in eyes with rAAV-angiostatin injection was decreased as compared with eyes with rAAV-lacZ injection. Original magnification was 200X.
###end p 49
###begin p 50
###xml 145 153 145 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f4">Figure 4</xref>
###xml 164 168 <span type="species:ncbi:10116">rats</span>
The retinal FITC-BSA fluorescence intensity was calculated and normalized to plasma fluorescence intensity by image analysis of serial sections (Figure 4). Four SD rats were represented by the number of sections to be examined at each timepoint. The mean retinal FITC-BSA fluorescence intensity in eyes receiving rAAV-angiostatin injection was 2.99+/-0.62 pixels at 5 days, 3.42+/-0.38 pixels at 10 days, and 3.30+/-0.40 pixels at 15 days after induction of diabetes. The retinal FITC-BSA fluorescence intensity in eyes receiving rAAV-lacZ injection was 3.59+/-0.31 pixels at 5 days, 3.77+/-0.51 pixels at 10 days, and 3.71+/-0.47 pixels at 15 days after induction of diabetes. Quantitative analysis showed that the fluorescence was decreased in eyes receiving rAAV-angiostatin as compared to eyes receiving rAAV-lacZ at 5 days (t=3.67, n=49, p=0.001), 10 days (t=3.94, n=51, p<0.001), and 15 days (t=3.52, n=56, p=0.001) after induction of diabetes.
###end p 50
###begin p 51
###xml 152 156 <span type="species:ncbi:10116">Rats</span>
###xml 1153 1157 <span type="species:ncbi:10116">rats</span>
Quantification of vascular leakage in experimental diabetes. FITC-BSA fluorescence intensity was measured by image analysis in serial retinal sections. Rats each received an intravenous injection of FITC-BSA were sacrificed at 5, 10, and 15 days after induction of diabetes. The average retinal FITC-BSA fluorescence intensity was calculated and normalized to plasma fluorescence intensity. The retinal FITC-BSA fluorescence intensity in eyes receiving rAAV-angiostatin injection was 2.99+/-0.62 pixels at 5 days, 3.42+/-0.38 pixels at 10 days and 3.30+/-0.40 pixels at 15 days after induction of diabetes. The retinal FITC-BSA fluorescence intensity in eyes receiving rAAV-lacZ injection was 3.59+/-0.31 pixels at 5 days, 3.77+/-0.51 pixels at 10 days and 3.71+/-0.47 pixels at 15 days after induction of diabetes. The normalized FITC-BSA fluorescence intensity in eyes receiving rAAV-angiostatin was decreased as compared to eyes receiving rAAV-lacZ at 5 days (t=3.67, n=49, p=0.001), 10 days (t=3.94, n=51, p<0.001), and 15 days (t=3.52, n=56, p=0.001) after STZ-induction of diabetes. The asterisk indicates a p less than or equal to 0.001. Four SD rats were represented by the number of sections (n) to be examined.
###end p 51
###begin title 52
rAAV-angiostatin influence on occludin loss
###end title 52
###begin p 53
###xml 838 846 824 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f5">Figure 5</xref>
###xml 0 4 <span type="species:ncbi:10116">Rats</span>
Rats receiving rAAV-angiostatin in their right eyes and rAAV-lacZ in their left eyes were sacrificed, and their eyes were enucleated for western blotting analysis at 1, 5, 10, and 15 days after induction of diabetes. The retinal occludin content in normal control eye was 42.35+/-2.67 pixels. No differences in retinal occludin content were detected between eyes receiving rAAV-lacZ and rAAV-angiostatin injection at 1 (rAAV-lacZ: 45.82+/-3.08 pixels, rAAV-angiostatin: 43.62+/-2.78) and 5 days (rAAV-lacZ: 38.96+/-2.22 pixels, rAAV-angiostatin: 40.65+/-3.46 pixels) after induction of diabetes. Ten days after diabetes induction, retinal occludin content in eyes that received rAAV-lacZ was 11.35+/-3.57 pixels and 34.73+/-3.17 pixels in eyes that received rAAV-angiostatin occludin, a statistically significant reduction (n=5, p=0.041, Figure 5). The retinal occludin content in rAAV-lacZ-treted eyes was higher (26.32+/-3.46 pixels) at 15 days after induction of diabetes than it was at 10 days, and there was no difference in rAAV-angiostatin-treated animals (29.21+/-2.94 pixels).
###end p 53
###begin p 54
###xml 277 278 277 278 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 341 342 341 342 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 120 124 <span type="species:ncbi:10116">rats</span>
###xml 335 339 <span type="species:ncbi:10116">rats</span>
The effect of rAAV-angiostatin gene transfer on retinal occludin expression 10 days after STZ-induction of diabetes The rats received intravitreal injection of rAAV-angiostatin in the right eyes and rAAV-lacZ in left eyes, and diabetes was induced three weeks after injection. A: Each blot is a representative of the results from five rats. B: Occludin levels were semi-quantified by densitometry, and normalized to actin. The rAAV-angiostatin significantly decreased retinal occludin loss as compared to eyes receiving rAAV-lacZ injection at 10 days after induction of diabetes (the asterisk indicates significance using the Wilcoxon signed rank test, n=5, p=0.041).
###end p 54
###begin title 55
rAAV-angiostatin influence on VEGF expression
###end title 55
###begin p 56
###xml 331 342 325 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f6">Figure 6, p</xref>
###xml 159 162 <span type="species:ncbi:10116">rat</span>
One day after diabetes induction, we observed rAAV-angiostatin-mediated influence of retinal VEGF expression. The retinal VEGF expression in normal control SD rat was 7.56+/-1.25 pixels. Retinal VEGF was 13.7+/-3.78 pixels (n=6) in rAAV-lacZ-treated eyes and decreased to 8.69+/-3.23 pixels (n=6) in rAAV-angiostatin-treated eyes (Figure 6, p=0.043). The retinal VEGF expression in eyes receiving rAAV-lacZ was 11.45+/-2.73 pixels at 5 days, 9.12+/-3.12 pixels at 10 days, and 10.41+/-3.36 pixels at 15 days after induction of diabetes. The retinal VEGF expression in rAAV-angiostatin-treated eyes was 9.52+/-3.96 pixels at 5 days, 8.31+/-2.67 pixels at 10 days, and 10.16+/-3.36 pixels at 15 days after induction of diabetes. There was no statistical difference in retinal VEGF expression in rAAV-lacZ- and rAAV-angiostatin-treated eyes at 5, 10, and 15 days after induction of diabetes.
###end p 56
###begin p 57
###xml 113 114 113 114 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 172 173 172 173 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 166 170 <span type="species:ncbi:10116">rats</span>
The effect of rAAV-angiostatin gene transfer on retinal VEGF expression at 1 day after STZ-induction of diabetes A: The blots show representative of results from six rats. B: VEGF levels were semiquantified by densitometry and normalized by actin levels. rAAV-angiostatin decreased the expression of VEGF as compared to eyes with rAAV-lacZ injection (the asterisk indicates significance using the Wilcoxon signed rank test, n=6, p=0.043).
###end p 57
###begin title 58
PEDF expression
###end title 58
###begin p 59
###xml 163 172 163 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f7">Figure 7A</xref>
###xml 375 384 375 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f7">Figure 7B</xref>
There was no significant difference in retinal PEDF expression between eyes exposed to rAAV-angiostatin and rAAV-lacZ at 1, 5, 10, or 15 days after STZ injection (Figure 7A). To further evaluate if rAAV-angiostatin could influence PEDF expression, we infected HUVEC-2C cells with rAAV-angiostatin. No PEDF expression was detected in rAAV-angiostatin-infected HUVEC-2C cells (Figure 7B). Western blot analysis of PEDF plasmid-transfected HUVEC-2C cells was used as a positive control.
###end p 59
###begin p 60
###xml 72 73 72 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 236 237 236 237 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
The effect of rAAV-angiostatin gene transfer on retinal PEDF expression A: There was no apparent difference in retinal PEDF expression between eyes exposed to rAAV-angiostatin and rAAV-lacZ. at 1, 5, 10, or 15 days after STZ injection. B: There was no increase in PEDF expression in HUVEC-2C cells receiving rAAVangiostatin compared to control HUVEC-2C cells. Western blotting of the PEDF plasmid-transfected HUVEC-2C cells was used as a positive control.
###end p 60
###begin title 61
rAAV-angiostatin-mediated downregulation of phospho-p42/p44 MAP kinase
###end title 61
###begin p 62
###xml 310 321 304 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f8">Figure 8, p</xref>
###xml 67 70 <span type="species:ncbi:10116">rat</span>
The retinal phosphor-p42/p44 MAP kinase level of normal control SD rat was 7.03+/-1.22 pixels. At one day after STZ injection, retinal phosphor-p42/p44 MAP kinase levels were 7.43+/-0.93 pixels (n=5) in eyes receiving rAAV-lacZ, and was decreased to 4.58+/-1.36 pixels(n=5) in eyes receiving rAAV-angiostatin (Figure 8, p=0.043). No effect was observed at 5 days after STZ injection (5.64+/-1.28 pixels for eyes receiving rAAV-lacZ, and 5.44+/-1.65 pixels for eyes receiving rAAV-angiostatin), 10 days (5.13+/-0.92 pixels for eyes receiving rAAV-lacZ, and 5.97+/-1.87 pixels for eyes receiving rAAV-angiostatin) and 15 days (7.37+/-1.33 pixels for eyes receiving rAAV-lacZ, and 7.25+/-2.65 pixels for eyes receiving rAAV-angiostatin)
###end p 62
###begin p 63
###xml 142 143 142 143 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 313 314 313 314 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
The effect of rAAV-angiostatin gene transfer on retinal phosphorylation of p42/p44 MAP kinases at 1 day after STZ-based induction of diabetes A: Representative blots show retinal phospho-p42/44 MAP kinase and total p42/44 MAP kinase in normal control eyes and in eyes injected with rAAV-lacZ or rAAV-angiostatin. B: Retinal levels of phosphor-p42/p44 MAP kinase one day after STZ-based induction of diabetes was reduced by rAAV-angiostatin (the asterisk indicates significance using the Wilcoxon signed rank test, n=5, p=0.043).
###end p 63
###begin title 64
Discussion
###end title 64
###begin p 65
###xml 111 112 111 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 113 114 113 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r32">32</xref>
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r34">34</xref>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
###xml 632 634 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r36">36</xref>
Retinal vascular leakage is a major cause of macular edema in diabetic retinopathy and other retinal diseases [1-6]. Traditionally, laser photocoagulation has been used to reduce the vascular leakage induced by diabetes [32,33]. Recently, anti-inflammatory drugs such as triamcinolone [34], or pars-plana vitrectomy with or without internal limiting membrane peeling [35] have been used to attenuate the diabetic macular edema. Due to the duration and severity, an ideal strategy would be to develop an approach involving a single administration of a vector that would result in long-term expression of a suitable therapeutic gene [36].
###end p 65
###begin p 66
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 104 106 104 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 222 223 222 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 227 229 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r37">37</xref>
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r38">38</xref>
###xml 475 476 475 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 477 479 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r37">37</xref>
###xml 605 606 605 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 672 676 <span type="species:ncbi:10116">rats</span>
rAAV vectors are highly efficient gene delivery systems which can facilitate long-term transduction [22,23]. We have previously reported in several animal models a gene transfer technique based on the use of rAAV vectors [8,23,25,26,37,38]. This gene transfer technique is particularly attractive for treating ocular disease for reasons of accessibility and long term transduction, and potentially because it would enable clinicians to avoid repeated intravitreal injection [8,37]. We previously reported suppression of laser-induced choroidal neovascularization by an rAAV vector expressing angiostatin [8]. Here, we report that vascular leakage in experimental diabetic rats can be reduced by angiostatin delivery via an rAAV vector. These results suggest that rAAV-angiostatin could be beneficial in the treatment of diabetic macular edema.
###end p 66
###begin p 67
###xml 95 97 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 426 427 426 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 356 359 <span type="species:ncbi:10116">rat</span>
Angiostatin is a proteolytic fragment of plasminogen and contains kringle domains 1 through 4 [10]. It has been determined that angiostatin is a potent anti-angiogenic factor [11] that can inhibit endothelial cell migration and induce apoptosis in these cells [12]. Recently, intravitreal injection of angiostatin was found to reduce vascular leakage in a rat model of experimental diabetes and in oxygen induced retinopathy [9]. In the same report, the expression of VEGF was found to be downregulated by angiostatin.
###end p 67
###begin p 68
###xml 104 106 104 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 107 109 107 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r39">39</xref>
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r39">39</xref>
###xml 334 336 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r40">40</xref>
###xml 433 435 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 940 942 940 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 943 945 943 945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 946 948 946 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r39">39</xref>
###xml 949 951 949 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r40">40</xref>
VEGF is a potent angiogenic factor, expression of which is increased in eyes with diabetic retinopathy [13,14]. VEGF, which is also known as vascular permeability factor (VPF) [39], increases microvascular permeability at very low concentrations [39], and may be important in the pathogenesis of vascular leakage induced by diabetes [40]. Angiostatin-induced reduction of vascular leakage occurs through blockade of VEGF expression [15]. In our study, retinal VEGF expression decreased in eyes receiving rAAV-angiostatin as compared to rAAV-lacZ treated eyes at one and five days after induction of diabetes. Vascular leakage was also decreased in eyes receiving intravitreal injection of rAAV-angiostatin compared to the contralateral eyes receiving rAAV-lacZ injection at 5, 10, and 15 days after induction of diabetes.These results are consistent with previous reports that angiostatin reduces the vascular leakage via blockade of VEGF [13-15,39,40]. How angiostatin reduces vascular leakage through inhibition of VEGF production is still under investigation.
###end p 68
###begin p 69
###xml 75 77 75 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r41">41</xref>
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r42">42</xref>
###xml 350 352 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r43">43</xref>
###xml 654 662 654 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f8">Figure 8</xref>
###xml 701 705 <span type="species:ncbi:10116">rats</span>
It is known that p42/p44 MAP kinase phosphorylation is induced by hypoxia [41]. This phosphorylation is diminished by angiostatin in microvascular endothelial cells [42]. Phosphorylation of p42/p44 MAP kinase promotes VEGF expression by activating its transcription via recruitment of the AP-2/Sp1 (activator protein-2) complex of the VEGF promoter [43]. It is therefore plausible that inhibition of phosphorylation of p42/p44 MAP kinase by angiostatin suppresses VEGF expression under conditions of hypoxia. In our study, retinal phosphorylation of p42/p44 MAP kinase decreased in eyes receiving rAAV-angiostatin at one day after induction of diabetes (Figure 8). Our results in STZ-induced diabetic rats suggest that angiostatin suppresses VEGF expression by inhibition of phosphorylation of the p42/p44 MAP kinase.
###end p 69
###begin p 70
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r44">44</xref>
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r45">45</xref>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 376 378 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r46">46</xref>
###xml 449 451 449 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 518 520 518 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 571 573 571 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r47">47</xref>
###xml 574 576 574 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r48">48</xref>
###xml 675 677 675 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 743 747 <span type="species:ncbi:10116">rats</span>
###xml 989 993 <span type="species:ncbi:10116">rats</span>
BRB breakdown is a hallmark of vascular leakage in diabetic retinopathy and other retinal vascular diseases [44,45]. The tight junctions between the retinal vascular endothelial cells constitute an essential structured component of BRB [18]. This barrier limits diffusion of molecules from vessel lumen to the tissue, and thereby maintains the microenvironment of the retina [46]. The barrier protein occludin is decreased in experimental diabetes [21]. VEGF stimulates phosphorylation and redistribution of occludin [19], which is subsequently endocytosed and degraded [47,48]. This process is closely related to the elevated vascular permeability in experimental diabetes [18]. In our study, retinal occludin content in STZ-induced diabetic rats was preserved in eyes receiving rAAV-angiostatin as compared to eyes receiving rAAV-lacZ. The rAAV-angiostatin-induced inhibition of VEGF may therefore suppress vascular leakage by preserving retinal occludin content in STZ-induced diabetic rats
###end p 70
###begin p 71
###xml 97 99 97 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r49">49</xref>
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r51">51</xref>
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r50">50</xref>
###xml 437 439 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 833 835 833 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r52">52</xref>
PEDF is a potent angiogenic inhibitor that is counter balanced by the angiogenic effect of VEGF [49-51]. Decreased expression of PEDF in retina is associated with ischemia-induced retinal neovascularization and proliferative diabetic retinopathy [50]. Recently, another proteolytic fragment of plasminogen-kringle 5 (K5) was noted to upregulate PEDF expression in a dose-dependent manner in vascular endothelial cells and in the retina [15]. In our study, there was no statistically significant difference between PEDF expression in eyes receiving rAAV-angiostatin and the contralateral eyes receiving rAAV-lacZ. Our results also revealed that rAAV-angiostatin did not upregulate PEDF expression in HUVEC-2C cells. However, PEDF expression has been shown to be induced at both the mRNA and protein level following injury in the eye [52]. Further research is warranted to explore the effect of rAAV-angiostatin on PEDF expression.
###end p 71
###begin p 72
###xml 443 445 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r53">53</xref>
###xml 124 128 <span type="species:ncbi:10116">rats</span>
###xml 389 392 <span type="species:ncbi:10116">rat</span>
###xml 702 712 <span type="species:ncbi:10116">Norway rat</span>
Our study showed that transgenic expression of rAAV-angiostatin can reduce retinal vascular leakage in STZ-induced diabetic rats. This effect is associated with downregulation of retinal VEGF and phospho-p42/p44 MAP kinase expression, and a reduction in the retinal occludin loss induced by diabetes. However, the vascular leakage and VEGF expression after induction of diabetes in the SD rat model was demonstrated to be a short-term effect [53]. Gene-based therapies can be as effective and viable as real treatment if long-term expression can be achieved. To demonstrate the long-term effect of rAAV-angiostatin on vascular leakage induced by diabetes, an alternative animal model such as the Brown-Norway rat could be used in a future study.
###end p 72
###begin p 73
###xml 77 78 77 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 67 75 <span type="species:ncbi:9606">patients</span>
###xml 352 360 <span type="species:ncbi:9606">patients</span>
###xml 477 485 <span type="species:ncbi:9606">patients</span>
Diabetic macular edema is a major cause of vision loss in diabetic patients [7]. On the basis of these findings, we believe that a similar vector and therapeutic gene could eventually be a useful strategy for long-term preventive or adjunctive therapy for macular edema induced by diabetes. It could serve as the basis for an alternative treatment for patients who are suffering from diabetic macular edema as well as a potentially preventive therapeutic modality for diabetic patients who are at risk for development of macular edema.
###end p 73
###begin title 74
Acknowledgements
###end title 74
###begin p 75
The authors thank Hong-Kong Chen, Ju-Yun Wu, and I-Pin Choung for excellent technical support. This study was supported by grants from National Science Council, Taiwan (NSC 94-2314-B-95-002, NSC 95-3112-B-195-001) and from the Mackay Memorial Hospital (MMH-E-95006, MMH-9501).
###end p 75
###begin title 76
References
###end title 76
###begin article-title 77
New diagnostic criteria and classification of diabetes--again?
###end article-title 77
###begin article-title 78
Pharmacological management of diabetes: recent progress and future perspective in daily drug treatment.
###end article-title 78
###begin article-title 79
Type 2 diabetes: epidemiology, pathophysiology, and diagnosis.
###end article-title 79
###begin article-title 80
Diabetic retinopathy.
###end article-title 80
###begin article-title 81
Treatment of diabetic retinopathy.
###end article-title 81
###begin article-title 82
Vascular dysfunction in diabetes mellitus.
###end article-title 82
###begin article-title 83
###xml 47 69 <span type="species:ncbi:272636">adeno-associated virus</span>
Suppression of choroidal neovascularization by adeno-associated virus vector expressing angiostatin.
###end article-title 83
###begin article-title 84
###xml 69 72 <span type="species:ncbi:10116">rat</span>
The effect of angiostatin on vascular leakage and VEGF expression in rat retina.
###end article-title 84
###begin article-title 85
Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma.
###end article-title 85
###begin article-title 86
Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD.
###end article-title 86
###begin article-title 87
Endothelial cell surface ATP synthase-triggered caspase-apoptotic pathway is essential for k1-5-induced antiangiogenesis.
###end article-title 87
###begin article-title 88
###xml 125 128 <span type="species:ncbi:10116">rat</span>
The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas.
###end article-title 88
###begin article-title 89
###xml 161 164 <span type="species:ncbi:10116">rat</span>
Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat.
###end article-title 89
###begin article-title 90
Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor: a possible mechanism for the anti-angiogenic activity of plasminogen kringle 5.
###end article-title 90
###begin article-title 91
Molecular mechanisms of vascular permeability in diabetic retinopathy.
###end article-title 91
###begin article-title 92
The molecular structure and function of the inner blood-retinal barrier. Penn State Retina Research Group.
###end article-title 92
###begin article-title 93
Regulation of tight junctions and loss of barrier function in pathophysiology.
###end article-title 93
###begin article-title 94
Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors.
###end article-title 94
###begin article-title 95
Altered expression of retinal occludin and glial fibrillary acidic protein in experimental diabetes. The Penn State Retina Research Group.
###end article-title 95
###begin article-title 96
Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group.
###end article-title 96
###begin article-title 97
###xml 36 42 <span type="species:ncbi:10090">murine</span>
Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases.
###end article-title 97
###begin article-title 98
###xml 58 80 <span type="species:ncbi:272636">adeno-associated virus</span>
###xml 93 96 <span type="species:ncbi:10116">rat</span>
Disease-inducible transgene expression from a recombinant adeno-associated virus vector in a rat arthritis model.
###end article-title 98
###begin article-title 99
###xml 37 59 <span type="species:ncbi:272636">adeno-associated virus</span>
Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus.
###end article-title 99
###begin article-title 100
###xml 51 73 <span type="species:ncbi:272636">adeno-associated virus</span>
Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist.
###end article-title 100
###begin article-title 101
###xml 58 62 <span type="species:ncbi:10116">rats</span>
GDNF gene therapy attenuates retinal ischemic injuries in rats.
###end article-title 101
###begin article-title 102
Vascular endothelial growth factor in diabetes induced early retinal abnormalities.
###end article-title 102
###begin article-title 103
Histamine H1 receptors mediate increased blood-retinal barrier permeability in experimental diabetes.
###end article-title 103
###begin article-title 104
Recruitment of marrow-derived endothelial cells to experimental choroidal neovascularization by local expression of vascular endothelial growth factor.
###end article-title 104
###begin article-title 105
###xml 189 194 <span type="species:ncbi:9031">chick</span>
Stimulation of dopaminergic amacrine cells by stroboscopic illumination or fibroblast growth factor (bFGF, FGF-2) injections: possible roles in prevention of form-deprivation myopia in the chick.
###end article-title 105
###begin article-title 106
Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization.
###end article-title 106
###begin article-title 107
Report 8: Photocoagulation treatment of proliferative diabetic retinopathy; clinical applications of diabetic retinopathy study (DRS) findings.
###end article-title 107
###begin article-title 108
Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number one.
###end article-title 108
###begin article-title 109
Intravitreal triamcinolone acetonide for diabetic macular edema.
###end article-title 109
###begin article-title 110
Modified grid laser photocoagulation versus pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema.
###end article-title 110
###begin article-title 111
###xml 64 86 <span type="species:ncbi:272636">adeno-associated virus</span>
Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene.
###end article-title 111
###begin article-title 112
###xml 36 58 <span type="species:ncbi:272636">adeno-associated virus</span>
Gene therapy for detached retina by adeno-associated virus vector expressing glial cell line-derived neurotrophic factor.
###end article-title 112
###begin article-title 113
###xml 12 34 <span type="species:ncbi:272636">adeno-associated virus</span>
Recombinant adeno-associated virus vector expressing glial cell line-derived neurotrophic factor reduces ischemia-induced damage.
###end article-title 113
###begin article-title 114
Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy.
###end article-title 114
###begin article-title 115
###xml 53 63 <span type="species:ncbi:10141">guinea pig</span>
Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor.
###end article-title 115
###begin article-title 116
H2O2 induces paracellular permeability of porcine brain-derived microvascular endothelial cells by activation of the p44/42 MAP kinase pathway.
###end article-title 116
###begin article-title 117
###xml 94 99 <span type="species:ncbi:9606">human</span>
Angiostatin diminishes activation of the mitogen-activated protein kinases ERK-1 and ERK-2 in human dermal microvascular endothelial cells.
###end article-title 117
###begin article-title 118
Signaling angiogenesis via p42/p44 MAP kinase cascade.
###end article-title 118
###begin article-title 119
Studies on the permeability of the blood-retinal barrier. 3. Breakdown of the blood-retinal barrier by circulatory disturbances.
###end article-title 119
###begin article-title 120
Studies on retinal blood flow. II. Diabetic retinopathy.
###end article-title 120
###begin article-title 121
The blood-retinal barriers system. Basic concepts and clinical evaluation.
###end article-title 121
###begin article-title 122
Occludin: a novel integral membrane protein localizing at tight junctions.
###end article-title 122
###begin article-title 123
Biogenesis of tight junctions: the C-terminal domain of occludin mediates basolateral targeting.
###end article-title 123
###begin article-title 124
Molecular mechanisms of blood vessel formation.
###end article-title 124
###begin article-title 125
Pigment epithelium-derived factor: a potent inhibitor of angiogenesis.
###end article-title 125
###begin article-title 126
Mechanistic insights on the inhibition of tumor angiogenesis.
###end article-title 126
###begin article-title 127
Angiostatic effect of penetrating ocular injury: role of pigment epithelium-derived factor.
###end article-title 127
###begin article-title 128
Genetic difference in susceptibility to the blood-retina barrier breakdown in diabetes and oxygen-induced retinopathy.
###end article-title 128

